Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial

Abstract

Persistent inflammation and immune activation are associated with lymph node fibrosis and end‐organ diseases in treatment‐suppressed people living with HIV (PLWH). We investigated the effect of switching to raltegravir and/or adding losartan on lymphoid tissue fibrosis and on the inflammatory/immune‐activation mediators in treated HIV patients.